17β-estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of erk1/2-mir-221 axis

A. Panic, J. Stanimirovic, M. Obradovic, S. Zafirovic, E. Sudar-Milovanovic, N. Petrovic, E.R. Isenovic

Article ID: 5287
Vol 32, Issue 6, 2018
DOI: https://doi.org/10.54517/jbrha5287
Received: 8 January 2019; Accepted: 8 January 2019; Available online: 8 January 2019; Issue release: 8 January 2019

Abstract

17β-Estradiol (E2) is known to negatively regulate inducible nitric oxide (NO) synthase (iNOS) expression via estrogen receptor alpha (ER-α) activation in aortic vascular smooth muscle cells.Therefore, we sought to determine whether E2 can inhibit iNOS in vivo in hepatic tissue via the activation of ER-α and whether extracellular signal-regulated kinases 1/2 (ERK1/2)-miR-221 axis is involved in this process. Male Wistar rats were treated with a bolus injection of E2 intraperitoneally (40 μg/kg), and 24 hours after treatment the animals were sacrificed and the livers excised. The protein levels of iNOS, p50 and p65 subunits of nuclear factor κB (NFκB), ERα, ERK1/2 and protein kinase B (Akt), as well as the association of ERα/Src in liver lysates were assessed by Western blot. The expression of hepatic miR-221 was analyzed by qRT-PCR. Results show that E2 reduced hepatic iNOS protein expression (p less than 0.01), the protein level of ERα (p less than 0.05), ERK1/2 (p less than 0.05), Akt phosphorylation (p less than 0.001) and miR-221 expression (p less than 0.05). In contrast, hepatic ERα/Src kinase association level (p less than 0.05) increased after E2 treatment. Our results indicate that E2 inhibits hepatic iNOS via molecular mechanisms involving the activation of the ER-α and inhibition of ERK1/2-miR-221 axis.


Keywords

estradiol;inducible nitric oxide synthase;Src kinase;extracellular signal-regulated kinase;miR-221


References

Supporting Agencies



Copyright (c) 2018 A. Panic, J. Stanimirovic, M. Obradovic, S. Zafirovic, E. Sudar-Milovanovic, N. Petrovic, E.R. Isenovic




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).